Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (amended). A method of treating the inflammation associated with a common cold or respiratory viral infection caused by human rhinovirus (HRV), other enteroviruses, coranavirus~~, influenza virus, parainfluenza virus~~ or respiratory syncytial ~~synctial~~ virus, ~~or adenovirus~~ in a human in need thereof which method comprises administering to said human an effective amount of a ~~CBSP/p38~~ CSBP/p38 inhibitor.

2 (original). The method according to Claim 1 wherein the respiratory viral infection exacerbates asthma.

3 (original). The method according to Claim 1 wherein the respiratory viral infection exacerbates chronic bronchitis.

4 (original). The method according to Claim 1 wherein the respiratory viral infection exacerbates chronic obstructive pulmonary disease.

5 (original). The method according to Claim 1 wherein the respiratory viral infection exacerbates otitis media.

6 (original). The method according to Claim 1 wherein the respiratory viral infection exacerbates sinusitis.

7 (original). The method according to Claim 1 wherein the respiratory viral infection is associated with a secondary bacterial infection, such as otitis media, sinusitis, or pneumonia.

8 (previously amended). The method according to Claim 1 wherein the CSBP/p38 inhibitor is administered with a second therapeutic agent.

9 (original). The method according to Claim 8 wherein the second therapeutic agent is an antiviral agent selected from ribavirin, amantidine, rimantidine, Pleconaril, AG 7088 or BTA-188; an antihistamine; a decongestant; a steroid; an antibiotic; an anti-inflammatory agent selected from an NSAID, a COX-1 or COX-2 inhibitor, ASA, or indomethacin; an influenza neuraminidase inhibitor selected from zamanivar (Relenza), oseltamivir (Tamiflu) or RWJ-270201.

10 (currently amended). The method according to Claim ~~1~~ 9 wherein the therapeutic agent is administered orally, topically (intranasal) or via inhalation (aerosol), or both topically and via inhalation.

11 (original). The method according to Claim 10 wherein the CSBP/p38 inhibitor is administered with a second therapeutic agent.

12 (original). The method according to Claim 11 wherein the second therapeutic agent may be administered by a different route than the CSBP/p38 inhibitor.

13 (original). The method according to Claim 12 wherein the second therapeutic agent is an antiviral agent ribavirin, amantidine, rimantidine, Pleconaril, AG 7088, BTA-188; an antihistamine; a decongestant; a steroid; an antibiotic; an anti-inflammatory agent selected from an NSAID, a COX-1 or COX-2 inhibitor, ASA, or indomethacin; or an influenza neuraminidase inhibitor selected from zamanivar (Relenza), oseltamivir(Tamiflu) or RWJ-270201.

14 (currently amended). The method according to Claim 1 wherein the CSBP/p38 inhibitor is selected from a compound disclosed in US Patent 5,716,972, US 5,686,455, US 5,656,644, US 5,593,992, US 5,593,991, US 5,663,334, US 5,670,527, US 5,559,137, 5,658,903, US 5,739,143, US 5,756,499, or US 5,716,955, US 5,658,903 ~~WO 98/25619~~, US 6,329,526 ~~WO 97/25048~~, US 6,251,914 ~~WO 99/01452~~, US 5,929,076 ~~WO 97/25047~~, US 5,756,499 ~~WO 99/01131~~, US 5,977,103 ~~WO 99/01130~~, US 6,096,748 ~~WO 97/33883~~, US 6,096,739 ~~WO 97/35856~~, US 6,235,760 ~~WO 97/35855~~, ~~WO 98/06715~~, US 6,414,150 ~~WO 98/07425~~, ~~WO 98/28292,WO 98/56377~~ US 2002156104A1, US 6,116,200 ~~WO 98/07966~~, US 6,569,871 ~~WO 99/01136~~ , US 6,362,193 ~~WO 99/17776~~, US 5,756,499 ~~WO 99/01131~~, US 5,756,499 ~~WO 99/01130~~, US

6,335,340 ~~WO 99/32121~~, ~~WO 00/26209, WO 99/58502~~ US 6,632,945, US 6,509,361 ~~WO 99/58523, WO 99/57101~~ US 6,316,466, US 6,130,235, ~~WO 99/61426, WO 99/59960~~ US 6,465,455, US 6,579,872, ~~WO 99/59959, WO 00/18738~~ US 6,455,520, US 6,509,363 ~~WO 00/17175, WO 99/17204~~ US 5,975,738, US 6,593,333 ~~WO 00/20402~~, US 6,528,508, ~~WO 99/64400, WO 00/01688, WO 00/07980, WO 00/07991~~ US 6,432,949, US 6,207,687, ~~WO 00/06563, WO 00/12074~~ US 6,410,540, US 6,184,226, ~~WO 00/12497, WO 00/31072~~ US 6,143,892, US 6,423,713 ~~WO 00/31063~~, US 5,800,385, ~~WO 00/23072, WO 00/31065~~ US 6,350,744, ~~WO 00/35911, WO 00/39116~~ US 6,511,997, US 6,319,921 ~~WO 00/43384~~, US 2001011135A1, ~~WO 00/41698, WO 97/36587,~~ US 5,859,041, ~~WO 97/47618, WO 97/16442, WO 97/16441,~~ US 5,717,100, ~~WO 97/12876, WO 98/7966,~~ US 6,116,200, US 2002156104A1, ~~WO 98/56377,~~ US 5,880,139 ~~WO 98/22109, WO 98/24782~~ US 6,096,753, US 6,096,753, ~~WO 98/24780, WO 98/22457~~ US 6,180,643, ~~WO 98/52558, WO 98/52941~~ US 6,087,381, US 5,932,576, ~~WO 98/52937,~~ US 6,423,713, ~~WO 98/52940, WO 98/56788~~ US 6,602,877, US 5,945,418, ~~WO 98/27098,~~ ~~WO 99/00357~~ US 6,093,742, US 5,965,583, ~~WO 98/47892,~~ ~~WO 98/47899, WO 99/03837~~ US 6,040,320, US 6,150,372, ~~WO 99/01441, WO 99/01449~~ US 6,300,347, US 5,981,710, ~~WO 99/03484,~~ ~~WO 95/09853~~ US 5,728,708, US 5,705,502,~~WO 95/09851, WO 95/09847~~ US 5,612,340, US 5,521,184, ~~WO 95/09852,~~ ~~WO 92/12154, WO 94/19350~~ US 5,670,503, US 6,498,274, US 6,498,274 ~~WO 99/15164, WO 98/50356~~ US 6,051,593, or US 6,432,988 ~~DE 19842833, or JP 2000 86657~~.

15 (previously amended). The method according to Claim 1 wherein the compound is 1-(1,3-Dihydroxyprop-2-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl)imidazole, or a pharmaceutically acceptable salt thereof.

16 (previously amended) The method according to Claim 1 wherein the compound is *trans*-1-(4-Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4-yl]imidazole; 1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)imidazole; or (4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-imidazole.

17 (previously amended) The method according to Claim 1 wherein the compound is VX-745, RWJ 67657, RWJ-68354, ZM 336372, SU 4984 or RPR-200765A.

18 (currently amended). A method of treating the inflammation associated with influenza induced pneumonia in a human in need thereof which method comprises administering to said human an effective amount of a CBSP/p38 inhibitor.

19 (currently amended). The method according to ~~Claims~~ Claim 18 wherein the CSBP/p38 inhibitor is administered with a second therapeutic agent.

20 (original) The method according to Claim 19 wherein the second therapeutic agent is an antiviral agent ribavirin, amantidine, rimantidine, Pleconaril, AG 7088, BTA-188; an antihistamine; a decongestant; a steroid; an antibiotic; an anti-inflammatory agent selected from an NSAID, a COX-1 or COX-2 inhibitor, ASA, or indomethacin; or an influenza neuraminidase inhibitor selected from zamanivar (Relenza), oseltamivir (Tamiflu) or RWJ-270201.

21 (original) The method according to Claim 18 wherein the therapeutic agent is administered orally, topically (intranasal) or via inhalation (aerosol), or both topically and via inhalation.

22 (original) The method according to Claim 21 wherein a second therapeutic agent may be administered by a different route than the CSBP/p38 inhibitor.

23 (previously amended) The method according to Claim 18 wherein the CSBP/p38 inhibitor is selected from a compound disclosed in US Patent 5,716,972, US 5,686,455, US 5,656,644, US 5,593,992, US 5,593,991, US 5,663,334, US 5,670,527, US 5,559,137, 5,658,903, US 5,739,143, US 5,756,499, or US 5,716,955, US 5,658,903 ~~WO 98/25619~~, US 6,329,526 ~~WO 97/25048~~, US 6,251,914 ~~WO 99/01452~~, US 5,929,076 ~~WO 97/25047~~, US 5,756,499 ~~WO 99/01131~~, US 5,977,103 ~~WO 99/01130~~, US 6,096,748 ~~WO 97/33883~~, US 6,096,739 ~~WO 97/35856~~, US 6,235,760 ~~WO 97/35855, WO 98/06715~~, US 6,414,150 ~~WO 98/07425~~, ~~WO 98/28292,WO 98/56377~~ US 2002156104A1, US

6,116,200 ~~WO 98/07966~~, US 6,569,871 ~~WO 99/01136~~ , US 6,362,193 ~~WO 99/17776~~, US 5,756,499 ~~WO 99/01131~~, US 5,756,499 ~~WO 99/01130~~, US 6,335,340 ~~WO 99/32121~~, ~~WO 00/26209, WO 99/58502~~ US 6,632,945, US 6,509,361 ~~WO 99/58523, WO 99/57101~~ US 6,316,466, US 6,130,235, ~~WO 99/61426, WO 99/59960~~ US 6,465,455, US 6,579,872, ~~WO 99/59959, WO 00/18738~~ US 6,455,520, US 6,509,363 ~~WO 00/17175, WO 99/17204~~ US 5,975,738, US 6,593,333 ~~WO 00/20402~~, US 6,528,508, ~~WO 99/64400, WO 00/01688, WO 00/07980, WO 00/07991~~ US 6,432,949, US 6,207,687, ~~WO 00/06563, WO 00/12074~~ US 6,410,540, US 6,184,226, ~~WO 00/12497, WO 00/31072~~ US 6,143,892, US 6,423,713 ~~WO 00/31063~~, US 5,800,385, ~~WO 00/23072, WO 00/31065~~ US 6,350,744, ~~WO 00/35911, WO 00/39116~~ US 6,511,997, US 6,319,921 ~~WO 00/43384~~, US 2001011135A1, ~~WO 00/41698, WO 97/36587~~, US 5,859,041, ~~WO 97/47618, WO 97/16442, WO 97/16441~~, US 5,717,100, ~~WO 97/12876, WO 98/7966~~, US 6,116,200, US 2002156104A1, ~~WO 98/56377~~, US 5,880,139 ~~WO 98/22109, WO 98/24782~~ US 6,096,753, US 6,096,753, ~~WO 98/24780, WO 98/22457~~ US 6,180,643, ~~WO 98/52558, WO 98/52941~~ US 6,087,381, US 5,932,576, ~~WO 98/52937~~, US 6,423,713, ~~WO 98/52940, WO 98/56788~~ US 6,602,877, US 5,945,418, ~~WO 98/27098~~, ~~WO 99/00357~~ US 6,093,742, US 5,965,583, ~~WO 98/47892~~, ~~WO 98/47899, WO 99/03837~~ US 6,040,320, US 6,150,372, ~~WO 99/01441, WO 99/01449~~ US 6,300,347, US 5,981,710, ~~WO 99/03484~~, ~~WO 95/09853~~ US 5,728,708, US 5,705,502, ~~WO 95/09851, WO 95/09847~~ US 5,612,340, US 5,521,184, ~~WO 95/09852~~, ~~WO 92/12154, WO 94/19350~~ US 5,670,503, US 6,498,274, US 6,498,274 ~~WO 99/15164, WO 98/50356~~ US 6,051,593, or US 6,432,988 ~~DE 19842833~~, ~~or JP 2000 86657~~.

24 (previously amended). The method according to Claim 18 wherein the compound is 1-(1,3-Dihydroxyprop-2-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl)imidazole, or a pharmaceutically acceptable salt thereof.

25 (previously amended) The method according to claim 18 wherein the compound is *trans*-1-(4-Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4-yl]imidazole; 1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)imidazole; or (4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-imidazole.